Strong chart on $PDII, bullish consolidation after it's recent strong move, another leg up in the not too distant future.

http://chartdiligence.com/pdii-healthy-consolidation-above-old-resistance-levels-above-moving-averages/

$PDII recent news/filings

bullish
double bottom
high green volume

## source: finance.yahoo.com

Mon, 06 Jul 2015 17:46:08 GMT ~ Aetna Publishes Favorable Coverage Policy for ThyGenX™, Interpace Diagnostics' Thyroid Mutation Panel

[at noodls] - PARSIPPANY, N.J., July 6, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) subsidiary Interpace Diagnostics announced today that effective June 2015, ThyGenX™,i the company's genetic mutation panel, has been ...

read full: http://www.noodls.com/view/BBEE21D0462543948B85DF32D523D0B87A581AC2
*********************************************************

Mon, 06 Jul 2015 17:37:00 GMT ~ Aetna Publishes Favorable Coverage Policy for ThyGenX™, Interpace Diagnostics' Thyroid Mutation Panel

[PR Newswire] - PARSIPPANY, N.J., July 6, 2015 /PRNewswire/ -- PDI, Inc. (PDII) subsidiary Interpace Diagnostics announced today that effective June 2015, ThyGenX™,i the company's genetic mutation panel, has been approved by Aetna for assessing fine needle aspiration (FNA) samples from indeterminate thyroid nodules. Aetna's coverage decision now means that ThyGenX is considered medically necessary. Aetna covers 46 million lives and its positive coverage decision brings the total number of lives covered for ThyGenX to more than 100 million. Guidelines from the National Comprehensive Cancer Network (NCCN) indicate that molecular diagnostic approaches may be useful in the evaluation of thyroid FNA samples that are indeterminate to assist in patient management, including identifying patients who are appropriate candidates for surgery and those for whom surveillance is appropriate.

read full: http://finance.yahoo.com/news/aetna-publishes-favorable-coverage-policy-173700985.html
*********************************************************

Tue, 09 Jun 2015 13:07:47 GMT ~ PDI INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150609/pdii8-k_a.html
*********************************************************

Mon, 08 Jun 2015 20:15:48 GMT ~ PDI INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150608/pdii8-k.html
*********************************************************

Mon, 25 May 2015 23:39:05 GMT ~ DMCI PDI files fixed rate retail bonds to SEC

[at noodls] - 5/25/2015 Material Information/Transactions C02842­2015 SECURITIES AND EXCHANGE COMMISSION SEC FORM 17­C CURRENT REPORT UNDER SECTION 17 OF THE SECURITIES REGULATION CODE AND SRC RULE 17.2(c) THEREUNDER ...

read full: http://www.noodls.com/view/4EF9B3E34050348B080C49AE04A2DA490F7B0268
*********************************************************

$PDII charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$PDII company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PDII/company-info
Ticker: $PDII
OTC Market Place: Not Available
CIK code: 0001054102
Company name: PDI, Inc.
Company website: http://www.pdi-inc.com
Incorporated In: DE, USA



$PDII share structure

## source: otcmarkets.com

Market Value: $30,615,329 a/o Jul 14, 2015
Shares Outstanding: 16,198,587 a/o May 07, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$PDII extra dd links

Company name: PDI, Inc.
Company website: http://www.pdi-inc.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PDII/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PDII/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PDII+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PDII+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PDII+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PDII/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PDII/news - http://finance.yahoo.com/q/h?s=PDII+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PDII/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PDII/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PDII/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PDII/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PDII/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PDII/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PDII/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PDII/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PDII+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PDII
DTCC (dtcc.com): http://search2.dtcc.com/?q=PDI%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PDI%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PDI%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.pdi-inc.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.pdi-inc.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.pdi-inc.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PDII/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PDII
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PDII/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PDII/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PDII/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001054102&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PDII/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PDII/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PDII/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PDII/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PDII&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PDII
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PDII/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PDII+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PDII+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PDII
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PDII
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PDII+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PDII/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PDII+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PDII.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PDII
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PDII/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PDII/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PDII/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PDII/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PDII
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PDII
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PDII:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PDII
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PDII



$PDII DD Notes ~ http://www.ddnotesmaker.com/PDII

I back in PDII as of today.Looking for a turn around play and a possible buy out ...BUY

Get in while you can. Insider buying at 1.71, 57K shares. Possible takeover target, company expects 2014 sales of 121M to 123M and expects to end year with 21 to 23M in cash. Market cap currently under 28M so it trading at a little over cash value. great buy in my opinion!!!!

this was alerted again in a daily group that I am a part of, they feel a short term target into the 1.90's coming soon . . .

This looks like its ready to explode to me

Seem like coming off its 52 week low this should be ready to continue a move up tomorrow

Alert PDII , this was alerted in a trading group that I am a member of, we have over 300 in the group, so many eyes are on it, they are looking for a nice move into the 1.90's . . . .

Am I the only one watching this????

This looks to be ready for a good bounce

This was great news? Liability personel? http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107690785&txt2find=PDII

Wow looks like the bottom is in here >>

Good afternoon DI, Inc. (PDII) looking for a strong hour of power!

7:31AM PDI Inc enters into collaboration agreement to commercialize molecular diagnostic tests (PDII) 4.62 : Co announced the signing of a collaboration agreement with a privately held molecular diagnostics co to commercialize the co's molecular diagnostic tests. The initial test to be commercialized is fully developed. Under the terms of the collaboration agreement, PDI has paid the co an initial fee of $1.5 mln and has received an option to purchase the co. The option price is dependent on the achievement of certain milestones during the collaboration period and could be up to $6 mln if all milestones are achieved at their maximum levels. PDI can terminate the collaboration agreement if all milestones are not achieved within one year and would receive a $1 mln termination fee from the co. If all milestones are achieved within one year and PDI has not exercised its option, the co can require PDI to exercise the option to purchase the co or terminate the collaboration agreement and pay PDI a termination fee of approximately $2 mln. If PDI purchases the co, in addition to the option price based on the achievement of milestones, beginning in 2015, PDI would pay a royalty of 7% on annual net revenue up to $50 mln with escalating royalty percentages for higher annual net revenue capped at 11% for annual net revenue in excess of $100 mln.

~ $PDII ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$PDII has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "PDII" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "PDII": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=PDII ~
Search Ihub for "PDII" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=PDII ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

12:50AM PDI Inc wins new buisness valued at $57 mln (PDII) 8.00 : Co announces the signing of a contract with a new customer to provide promotional services across PDI's multiple communications channels that will target primary care physicians. The contract is subject to FDA product approval. The contract is expected to generate total revenue to PDI of approximately $57 mln over the life of the two-year agreement, with $10-12 mln to be recorded over the second half of 2012

PDI Reports 2012 First Quarter Financial Results
Management to Host Conference Call Tomorrow, May 15, 2012 at 8:30AM ET
PR NewswirePress Release: PDI, Inc. – Mon, May 14, 2012 4:01 PM EDT

PARSIPPANY, N.J., May 14, 2012 /PRNewswire/ -- PDI, Inc. (PDII), today reported financial and operational results for the first quarter ended March 31, 2012. Summary financial and operating highlights include:

First quarter 2012 operating loss from continuing operations of $0.2 million improved 84% compared to the first quarter of 2011.
First quarter 2012 adjusted EBITDA was $0.7 million, compared to $0.1 million in the same period of 2011.
Announced new and renewal contracts totaling $16 million in revenues, approximately $13 million of which is expected to be recognized during 2012.

Condensed Summary Statements of Continuing Operations

1st Quarter Ended
March 31,*

2012

2011

Revenue, net


$ 31.7



$ 44.3







Gross profit



7.4



8.2

Operating expenses:





Compensation expense


4.6



5.3

Other SG&A



3.0



4.3

Total operating expenses


7.6



9.6







Operating loss



$ (0.2)



$ (1.4)


Other expense, net


(0.1)

Provision (benefit) for income tax


0.1



(1.0)

Loss from continuing operations


$ (0.3)



$ (0.4)



Diluted loss per share from continuing operations


$ (0.02)



$ (0.03)

*Unaudited

CEO Comments

"While first quarter 2012 revenues were below those of the same period in 2011, due primarily to the anticipated expiration of certain contracts, gross profit margins improved from 18% in 2011 to 23% in 2012, and expenses were reduced significantly due to continued cost control measures," stated Nancy Lurker, PDI's chief executive officer. "On the revenue front, we are pleased to note that, during the quarter, we began to see tangible conversion of our pipeline opportunities. This was reflected in our recent announcement of the signing of several new and renewal contracts. Together, these contracts are expected to generate total revenues of $16 million over the life of the contracts, and approximately $13 million in 2012. These business wins cover a range of promotional and communications agreements under which PDI will variously provide promotional and support services through the company's established relationship team, dedicated sales teams, clinical educators, and/or talent acquisition and training services. These latest contract wins and renewals are indicative of PDI's strong market position and reflect an upswing in market activity and momentum. Our new business pipeline remains robust and we are confident we will win additional contracts moving forward.

"Looking ahead, we are optimistic about our potential for growth and expect 2012 to be a year of continued execution on all fronts. The initiatives we have put into place have put the company on solid footing to achieve long-term profitability. As such, we remain highly focused on cost containment efforts, which have allowed us to drive down our cost basis, and improve our gross margin during the first quarter of this year. Additionally, as noted above, our core business and pipeline are strong, which we anticipate will lead to additional key contract wins and renewals over the remainder of the year. Meanwhile, we also continue to see interest and growth opportunities for Interpace BioPharma, which offers full product commercialization services. As such, we are committed to executing on our accelerated growth strategy for this important business unit.

"Finally, as previously announced, Frank Ryan, who has been on our Board for close to 10 years, will be retiring effective May 28. I would like to thank Frank for his many years of valuable service and important contributions to PDI."

Business Review – Continuing Operations

Revenue- For the first quarter of 2012, revenue of $31.7 million was 28% lower than the first quarter of 2011. The overall decrease is primarily attributable to lower Sales Services revenue.

Sales Services segment revenue for the first quarter of 2012 of $23.4 million was 45% lower than the first quarter of 2011. This decrease was primarily due to new contract wins being more than offset by certain contracts renewing for smaller amounts and the anticipated expiration of certain other contracts.
Marketing Services segment revenue for the first quarter of 2012 of $3.1 million was 57% higher than the first quarter of 2011. This increase was primarily due to higher Group DCA revenue.
Product Commercialization Services segment revenue for the first quarter of 2012 was $5.2 million from the fee-for-service arrangement in the Interpace BioPharma business unit, launched late in the second quarter of 2011. There was no revenue in the first quarter of 2011, as there were no ongoing product commercialization activities during that period.

Gross Profit- For the first quarter of 2012, gross profit of $7.4 million was 10% lower than the first quarter of 2011. At the same time, the gross profit percentage increased to 23% in 2012 from 18% in 2011. The overall decrease in gross profit dollars was driven by the decrease in Sales Services revenue. The overall increase in gross profit percentage was primarily driven by improved gross profit in Group DCA.

Sales Services segment gross profit for the first quarter of 2012 of $5.0 million was 44% lower than the first quarter of 2011. This decrease was primarily the result of lower revenue.
Marketing Services segment gross profit for the first quarter of 2012 of $1.2 million was higher when compared to 2011 as a result of increased revenue and improved margins at Group DCA. The segment's negative $0.6 million gross margin for the first quarter of 2011 was attributable in large part to the impact of acquisition accounting.
Product Commercialization Services segment gross profit for the first quarter of 2012 was $1.2 million. There was no gross profit in the first quarter of 2011, as there were no ongoing product commercialization activities during that period.

Total Operating Expenses- For the first quarter of 2012, total operating expenses were $7.6 million, $2.0 million lower than the first quarter of 2011, a decrease of 21%.

The decrease is attributable to a reduction in professional service and information technology costs as well as a significant reduction in costs at Group DCA due to the post acquisition right-sizing of that business.

Operating Loss- For the first quarter of 2012 the reported operating loss from continuing operations was $0.2 million, an improvement of approximately $1.2 million when compared to the operating loss of $1.4 million in the first quarter of 2011. This decrease in the operating loss can be attributed to the improved financial results at Group DCA, the addition of the product commercialization contract for the first quarter of 2012 and the reduction in total operating expenses.

Liquidity and Cash Flow- Cash and cash equivalents as of March 31, 2012 were $61.9 million, down $2.5 million from year end.

The company had net cash used in operations of $2.4 million for the first quarter of 2012. This decrease in cash is primarily attributable to the payments of severance and close-out costs associated with the sale of the Pharmakon business unit in December, 2011 as well as the right-sizing of the Group DCA unit.
As of March 31, 2012, the company's cash equivalents were predominantly invested in U.S. Treasury money market funds and the company had no commercial debt.

Non-GAAP Financial Measures
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, PDI has provided certain non-GAAP financial measures to help evaluate the results of its performance. These non-GAAP financial measures are related to the impact of the Group DCA operating results. The company believes that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing the company's ongoing business and operating performance. The company believes that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the company's financial results in the way that management views financial results.

Adjusted EBITDA is a metric used by management to measure liquidity. Adjusted EBITDA is defined as operating income (loss), plus depreciation and amortization, non-cash stock-based compensation, and other non-cash expenses.

http://finance.yahoo.com/news/pdi-reports-2012-first-quarter-200100679.html

~ Monday! $PDII ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $PDII ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=PDII&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=PDII&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=PDII
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PDII#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PDII+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PDII
Finviz: http://finviz.com/quote.ashx?t=PDII
~ BusyStock: http://busystock.com/i.php?s=PDII&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PDII >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

PDI, Inc. Announces $48 Million in Renewal Sales Contracts
PR NewswirePress Release: PDI, Inc. – Tue, Feb 14, 2012 7:48 AM EST

PARSIPPANY, N.J., Feb. 14, 2012 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII - News) today announced the signing of a three-year agreement with a current Top 5 global pharmaceutical client and renewal of a one-year engagement with a specialty pharmaceutical client. Approximately $48 million in revenue is expected to be generated in 2012 between both contracts.

Under the renewed contract with a current Top 5 pharmaceutical client, PDI will provide a dedicated sales team to exclusively promote products to primary care and specialty providers beginning Jan. 1, 2012. The first year of the three-year contract is expected to generate revenues to PDI of approximately $30 million; expected revenues for the outlying years will be determined prior to the start of each year.

The renewal contract with the specialty pharma company is to run for one year beginning Jan. 1, 2012, and is expected to generate revenues to PDI of approximately $18 million. Under the agreement, PDI will provide a dedicated sales team to call on women's health providers.

"These two contracts, which extend ongoing relationships, reaffirm the value that PDI can provide our customers and their confidence that we will consistently be able to deliver for them," said Nancy Lurker, Chief Executive Officer of PDI, Inc. "As a company, our goal is to provide customers with an outsourcing service offering a high return on investment and the strategic flexibility to help them most effectively deploy their resources."

http://www.insidercow.com/history/company.jsp?company=pdii&B1=Search!

Top Institutional Holders
Holder Shares % Out Value* Reported
DIMENSIONAL FUND ADVISORS LP 1,156,019 7.85 8,196,174 Jun 30, 2011
RENAISSANCE TECHNOLOGIES, LLC 586,100 3.98 4,155,449 Jun 30, 2011
Pekin Singer Strauss Asset Management 516,825 3.51 3,664,289 Jun 30, 2011
ESSEX INVESTMENT MANAGEMENT CO INC 494,708 3.36 3,507,479 Jun 30, 2011
GRANAHAN INVESTMENT MANAGEMENT INC. 306,060 2.08 2,169,965 Jun 30, 2011
HEARTLAND ADVISORS INC. 2,055,814 13.96 14,575,721 Jun 30, 2011
ROYCE & ASSOCIATES, LLC 1,567,797 10.65 11,115,680 Jun 30, 2011
VANGUARD GROUP, INC. (THE) 292,553 1.99 2,074,200 Jun 30, 2011
BlackRock Institutional Trust Company, N.A. 288,446 1.96 2,045,082 Jun 30, 2011
MESSNER & SMITH THEME/VALUE INVESTMENT MANAGEMENT, LTD 112,175 0.76 795,320 Jun 30, 2011

Top Mutual Fund Holders
Holder Shares % Out Value* Reported
HEARTLAND VALUE FUND 1,096,323 7.45 8,891,179 Mar 31, 2011
ROYCE MICRO-CAP FUND 1,015,694 6.90 7,201,270 Jun 30, 2011
ROYCE CAPITAL FUND-MICRO-CAP PORTFOLIO 478,720 3.25 3,394,124 Jun 30, 2011
Unified Series Trust-Appleseed Fund 444,402 3.02 3,150,810 Jun 30, 2011
DFA U.S. SMALL CAP VALUE SERIES 342,278 2.32 2,967,550 Apr 30, 2011
VANGUARD VARIABLE INSURANCE FUND-SMALL COMPANY GROWTH 305,400 2.07 2,476,794 Mar 31, 2011
VANGUARD TOTAL STOCK MARKET INDEX FUND 174,583 1.19 1,415,868 Mar 31, 2011
Managers AMG Funds-Essex Small/Micro Cap Growth Fund 137,616 0.93 975,697 Jun 30, 2011
DFA U.S. MICRO CAP SERIES 131,394 0.89 1,139,185 Apr 30, 2011
DFA U.S. SMALL CAP SERIES 126,989 0.86 1,100,994 Apr 30, 2011

7:46AM PDI Inc announces $55 mln agreement to market Rx product through 2013 for treatment of knee pain (PDII) 7.46 : Co announced that through a newly formed business unit, Interpace BioPharma, it has entered into a two-and-a-half-year, fee-for-service agreement with a pharmaceutical co to market in the U.S. and its territories a treatment for pain of the knee. The agreement is expected to generate ~$10 mln of revenues to PDI in 2011 and $55 mln over the life of the contract. The agreement, which runs through December 31, 2013, includes an option for a contract extension. Under the agreement, Interpace will provide a dedicated full-time sales team and a fully integrated strategic and operational management team that, together with the pharmaceutical company, are responsible for the U.S. commercialization of the product.